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Cytosolic compartmentalization through liquid-liquid
unmixing, such as the formation of RNA granules, is
involved in many cellular processes and might be
used to regulate signal transduction. However,
specific molecular mechanisms by which liquid-
liquid unmixing and signal transduction are coupled
remain unknown. Here, we show that during cellular
stress the dual specificity kinase DYRK3 regulates
the stability of P-granule-like structures and
mTORC1 signaling. DYRK3 displays a cyclic parti-
tioning mechanism between stress granules and
the cytosol via a low-complexity domain in its N
terminus and its kinase activity.When DYRK3 is inac-
tive, it prevents stress granule dissolution and the
release of sequestered mTORC1. When DYRK3 is
active, it allows stress granule dissolution, releasing
mTORC1 for signaling and promoting its activity by
directly phosphorylating the mTORC1 inhibitor
PRAS40. This mechanism links cytoplasmic com-
partmentalization via liquid phase transitions with
cellular signaling.
INTRODUCTION
The nucleus and cytosol of eukaryotic cells contain numerous
nonmembrane-bound compartments that consist of many
proteins involved in complex reactions, such as regulation of
the actin cytoskeleton and mRNA metabolism (Brangwynne
et al., 2009; Li et al., 2012). Well-known among these are
different types of RNA granules, microscopically visible accumu-
lations of messenger ribonucleo-protein (mRNP) (Anderson
and Kedersha, 2009; Eulalio et al., 2007). A complex repertoire
of mRNP-associated proteins determines whether mRNP
complexes remain silent, become translationally active, or are
degraded (Buchan and Parker, 2009). Particularly during stress-
ful conditions such as heat, oxidative and osmotic stress, virusinfection, and UV irradiation, translationally silenced mRNPs
accumulate into stress granules (SGs) (Anderson and Kedersha,
2008).
Recently, it has become clear that the accumulation of RNA
granules is reminiscent of concentration-dependent liquid-liquid
unmixing of complexes consisting of mRNA and proteins with
low complexity domains (Hyman and Simons, 2012; Kato
et al., 2012; Weber and Brangwynne, 2012). Although this may
be a unifying principle of compartmentalization without mem-
branes (Brangwynne et al., 2009), many fundamental questions
remain unanswered. For instance, are there specific molecular
regulators of this type of compartmentalization? Is such com-
partmentalization utilized to control signal transduction, analo-
gous to membrane-bound compartments? These questions
become apparent during cellular stress, when cells have to coor-
dinate SG condensation and dissolution with the control of
signaling pathways that initiate mRNA translation (Buchan and
Parker, 2009). Among these, the mechanistic target of rapamy-
cin (mTOR) signaling pathway takes a prominent role (Loewith
and Hall, 2011; Ma and Blenis, 2009; Sengupta et al., 2010;
Zoncu et al., 2011). Interestingly, in S. cerevisiae, TORC1 parti-
tions in heat-induced SGs, suggesting a coupling of SG conden-
sation and dissolution with TORC1 signaling and indicating
a physiological role of SGs in the spatiotemporal regulation of
TORC1 activity during stress (Takahara and Maeda, 2012).
How the regulation of SG condensation and TORC1 signaling
is organized is, however, unclear.
Here, we identify the dual specificity tyrosine-phosphoryla-
tion-regulated kinase 3 (DYRK3) as a protein with the ability to
condense P-granule-like speckles in the cytosol and to prevent
SG dissolution via its N-terminal domain when it is in a kinase-
inactive form. DYRK3 couples this to the control of mTORC1
signaling by keeping mTORC1 sequestered in SGs when inac-
tive and by phosphorylating PRAS40, a negative regulator of
mTORC1 (Sancak et al., 2007; Vander Haar et al., 2007), when
active. DYRK3 dynamically regulates its own partitioning
between SGs and the cytosol through its kinase activity, sug-
gesting a cyclic partitioning mechanism that couples compart-
mentalization through liquid phase transition with cellular
signaling.Cell 152, 791–805, February 14, 2013 ª2013 Elsevier Inc. 791
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Figure 1. An Image-Based Screen for Chemical Compound Inhibitors of Stress Granule Dissolution
(A) Schematic representation of the performed image-based screen for chemical compound inhibitors. HeLa cells were exposed to oxidative stress and allowed
to recover for 240 min in the presence of small compound inhibitors. The fractions of SG-positive cells were classified by immunostaining against PABP1,
automated microscopy and image analysis, feature extraction, and support vector machine (SVM) learning.
(legend continued on next page)
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RESULTS
An Image-Based Screen for Chemical Compound
Inhibitors that Delay Stress Granule Dissolution
To study the regulation of SG dissolution, we screened a custom
library of 246 small compound kinase inhibitors for their ability to
prolong the presence of SGs in HeLa cells during recovery from
arsenite-induced oxidative stress.We first exposed cells to arse-
nite for 45min, after whichwe allowed recovery for 240min in the
presence of small compound inhibitors at two different concen-
trations (Figure 1A and Table S1 available online). To monitor the
occurrence of SGs, we used immunofluorescence staining
against polyadenylate-binding protein 1 (PABP1), which gets re-
cruited to SGs upon stress, resulting in bright and easily detect-
able granules (Kedersha et al., 1999).
Compounds that were able to block SG dissolution for at
least three standard deviations above the mean of all treat-
ments were considered as significant hits (Z score R 3; red
dots). At 1 mM concentration, GSK-626616 and Jak3 inhibitor
IV were potent in blocking SG dissolution (Figure 1B, left
side), whereas at 10 mM concentration, harmine, Wee1/Chk1
inhibitor, CDK4 inhibitor III, CDK2 inhibitor IV, HMS3229I17,
and GSK-626616 were potent in blocking SG dissolution
(Figure 1B, right side). GSK-626616 was the most potent in
delaying SG dissolution at 1 mM, whereas harmine was present
in the top 4% of compounds that delayed SG dissolution at low
concentrations (Figure 1B, left side), and was most potent in
delaying SG dissolution at 10 mM.
To validate the seven identified compounds, we performed
a second stress recovery assay using time-lapse imaging of
U2OS cells stably expressing GFP-tagged Ras GTPase-
activating protein-binding protein 1 (G3BP1), another marker
for SGs (Ohn et al., 2008). Oxidative stress for 45 min caused
a rapid increase of SG-positive cells, followed by a rapid decline
in the subsequent recovery phase after arsenite washout (Fig-
ure 1C and Movie S1). The time-lapse imaging confirmed that
five compounds, GSK-626616, harmine, CDK2 inhibitor IV,
CDK4 inhibitor III, and Wee1/Chk1 inhibitor, reduced the decline
rate of the fraction of cells with G3BP1-positive SGs during
recovery.
We further excluded compounds that induce SG condensa-
tion in the absence of oxidative stress. Treatment of cells for
240 min with compounds revealed that CDK2 inhibitor IV, and
to a lesser extent Wee1/Chk1 inhibitor, induced SGs in the
absence of stress (Figure 1D). CDK4 inhibitor III, GSK-626616,
and harmine did not cause significant SG formation in HeLa cells
during 240 min of treatment.
Finally, we analyzedwhether the compounds have an effect on
the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2a)
at Ser51, which is induced by arsenite treatment and causes(B) Representation of Z-score normalized SG-indices of the small compound inhib
blue, compound conditions that are at least 3 SD above the mean of all treatme
(C) Summary of candidate compounds and representative images from the screen
lapse SG recovery assay in U2OS cells stably expressing GFP-G3BP1 are show
(D) Ability of compounds to induce SG condensation in the absence of stress and
from stress. Quantification of the fraction of SG-positive cells relative to arsenite-
shown. Data are represented as mean ± SD (n = 3).a translational arrest and rapid appearance of SGs (Anderson
and Kedersha, 2002). Interestingly, none of the compounds
could trigger the phosphorylation of eIF2a to levels comparable
with those induced by arsenite, but the Wee1/Chk1 inhibitor and
HMS3229I17 prevented full dephosphorylation of eIF2a after
recovery from oxidative stress (Figure 1D).
Of the three compounds, which were able to reduce the rate of
SGs dissolution without evoking de novo SG condensation or
affecting the phosphorylation state of eIF2a, two, GSK-626616
and harmine, are known inhibitors of DYRK family kinases (Erick-
son-Miller et al., 2007; Go¨ckler et al., 2009). GSK-626616 has
a reported IC50 of 0.7 nM for DYRK3, but the overall kinase spec-
ificity is unclear.
To obtain a kinome-wide view on the specificity of GSK-
626616, we profiled the inhibitory effect of GSK-626616 on
451 kinases in vitro (Karaman et al., 2008). At 0.1 mM, GSK-
626616 primarily inhibits DYRK family kinases (Figure S1A and
Table S2 available online) with a good selectivity (S score
(35) = 0.07), comparable to well-studied and highly specific
kinase inhibitors (Karaman et al., 2008). At 1 mM, GSK-626616
displays some off-target effects in vitro but still has reasonable
selectivity against DYRK family kinases (S score (35) = 0.12).
Harmine was previously tested on 67 kinases in vitro, and also
shows a specific inhibition of DYRK family kinases at 1 mM
(Bain et al., 2007), in particular of DYRK1A, DYRK2, and
DYRK3 (Go¨ckler et al., 2009).
Taken together, specific inhibitors of DYRK family kinases
delay the dissolution of SGs during recovery from stress in
a manner that does not involve classical SG condensation path-
ways via eIF2a.
DYRK3 Condenses P-Granule-like Speckles and
Partitions into Stress Granules
To investigate the subcellular localization of DYRKs, we tran-
siently expressedGFP-tagged versions in HeLa cells. Consistent
with a previous classification of DYRK family kinases by their
subcellular localization (Aranda et al., 2011), we found that
GFP-DYRK1A and GFP-DYRK1B localized to the nucleus (Fig-
ure S2A). Interestingly, GFP-DYRK3 localized predominantly
on distinct speckles distributed throughout the cytoplasm of
the cell (Figure 2A). This subcellular localization of GFP-DYRK3
was not seen for GFP-DYRK2 or GFP-DYRK4, the two other
class 2 DYRK family members (Figure S2A).
At low levels of expression, however, GFP-DYRK3 displayed
a homogeneous distribution throughout the cytoplasm and did
not condense in speckles (Figure 2B). When we correlated
GFP-DYRK3 condensation with its level of expression, we
discovered that it occurs in every cell when a certain threshold
expression level is reached (Figure 2B). Furthermore, following
GFP-DYRK3 speckles by time-lapse microscopy revealed thatitors at two different concentrations (see also Table S1). Controls are colored in
nts were considered as significant hits (Z scoreR 3; red dots).
, PubChem ID, chemical structure, reported IC50 values, and results of the time-
n. Data are represented as mean ± SD.
effects of compounds on eIF2a phosphorylation in the absence and recovery
treated cells (first bar graph) for each compound at indicated concentrations is
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Figure 2. DYRK3 Condenses in Speckles and Partitions in Stress Granules
(A) A confocal image stack of a HeLa cell transiently expressing GFP-DYRK3 that condensed into distinct speckles distributed throughout the cytoplasm.
(B) GFP-DYRK3 condenses P-granule-like speckles in a concentration-dependent manner. A total of 241 cells were automatically segmented using compu-
tational image analysis, mean fluorescent intensity was measured per cell, and cells containing a homogeneous distribution [H] or granules [G] of GFP-DYRK3
were classified by SVM training.
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the speckles move and merge in a liquid droplet-like manner
(Figure S2B and Movie S2). These observations are reminiscent
of P granule behavior in C. elegans (Brangwynne et al., 2009). To
test whether DYRK3 condenses RNA granule components, we
coexpressed myc-DYRK3 with GFP-GW182, a scaffold protein
of mRNA processing bodies (P bodies) in C. elegans, as well
as in vertebrates (Eulalio et al., 2007; Eystathioy et al., 2003).
When c-expressed, myc-DYRK3 and GFP-GW182 condense
in granules that were larger than formed by GFP-DYRK3 expres-
sion alone (Figure 2C).
Importantly, we observed that during oxidative and osmotic
stress, endogenous DYRK3, as well as GFP-DYRK3, localizes
to SGs (Figures 2D and 2E). Furthermore, DEAD box p54 protein
6 (DDX6)-positive P bodies, often in close proximity to SGs, were
found docked on GFP-DYRK3-positive granules (Figure S2C).
Moreover, endogenous DYRK3 remained localized to SGs after
240 min of stress recovery in the presence of DYRK inhibitors
(Figures 2F and S2D).
Thus, DYRK3 has the potential to condense granules in the
cytosol of human cells to which the mRNA-binding protein
GW182 can be recruited, and DYRK3 localizes to SGs during
oxidative and osmotic stress.
The N-Terminal Domain of DYRK3 Is Required for Stress
Granule Localization and Induces Stress Granules when
DYRK3 Kinase Activity Is Compromised
We next explored how inhibition of DYRK3 prevents SG disso-
lution. We observed that RNAi-mediated depletion of DYRK3,
or of the other DYRKs (not shown), did not disturb the conden-
sation of SGs during oxidative stress (not shown) or dissolution
of SGs after oxidative stress (Figure 3A). Instead, we discov-
ered that DYRK3 depletion, but not that of the other DYRKs
(not shown), reduced the block in SG dissolution caused by
GSK-626616 treatment. This suggests that inhibited DYRK3 is
in a state that specifically prevents the dissolution of SGs. In
support of this, we observed that expression of the kinase-
deficient point mutant DYRK3-K218M is sufficient to cause
the appearance of large cytoplasmic structures positive for
mRNA granule markers, on which GFP-DYRK3-K218M accu-
mulated, even in the absence of stress (Figure 3B). To test
whether a specific domain of DYRK3 mediates partitioning to
RNA granules, we generated a series of DYRK3 truncations
(Figure 3C). Expression of DYRK3-NT, which consists of the
N-terminal residues 1–188 and contains a predicted low-
complexity sequence (Figure S2E) but which excludes the
kinase domain and C-terminal end, induced the appearance
of large granules at high expression levels (Figure 3D). Similar
to SGs, these large granules had P bodies in close proximity
and stained positive for PABP1 (Figure 3E). Conversely, overex-
pression of DYRK3 without the N-terminal domain (DYRK3-(C) Transiently expressed GFP-GW182 and myc-DYRK3 display colocalization in
(D) Endogenous DYRK3 localizes to SGs induced by oxidative stress. Cells w
and PABP1.
(E) GFP-DYRK3 localizes to SGs induced by either oxidative or osmotic stress. He
for PABP1.
(F) Endogenous DYRK3 localizes to SGs induced by oxidative or osmotic stress a
allowed to recover in the presence of 1 mM GSK-626616 were immunostained foDNT) did not induce cytoplasmic granules and did not partition
in SGs induced by oxidative stress (Figure 3F).
Thus, inhibition of DYRK3 affects SG dissolution through
a specific state of DYRK3 when its kinase activity is compro-
mised. This state depends on the N-terminal domain of
DYRK3, which, when expressed alone or as part of kinase-defi-
cient DYRK3, is able to induce the appearance of SGs in the
absence of stress.
Inhibition of DYRKs Affects the Phosphorylation of
Proteins that Bind mRNA, Partition in Stress Granules,
and Are Downstream of mTORC1
To obtain insight into how cells couple SG condensation and
dissolution to signal transduction, we next studied which
signaling pathways are affected by the inhibition of DYRKs. To
reveal this, we studied changes in the phosphoproteome of cells
after GSK-626616 treatment, using a quantitative label-free
phosphoproteomic approach (Bodenmiller et al., 2010; Huber
et al., 2009) (Figure 4A). At two different time points, 30 min
and 12 hr of treatment respectively, we monitored the abun-
dance of phosphorylated peptides (Bodenmiller et al., 2007).
Of the overall 1,194 peptides identified, only those peptides
that were identified in three independent replicate experiments
and which were significantly enriched or depleted in the GSK-
626616-treated samples compared to control (DMSO) samples
(t test p value: < 0.1), where taken into account (Table S3). These
criteria yielded a total of 44 regulated phosphorylated peptides:
26 after short-term treatment and 18 after long-term treatment
with GSK-626616, respectively (Figure 4B). Six phosphorylated
peptides were found to be significantly enriched or depleted at
both time points.
Eighteen out of the 22 and 7 out of the 15 corresponding
proteins that were affected by short- and long-term treatment
with GSK-626616, respectively, were recently reported to asso-
ciate with mRNA or RNA granules (Baltz et al., 2012;
Castello et al., 2012; Elvira et al., 2006; Kato et al., 2012). In addi-
tion, mTORC1 signaling regulates five of the proteins affected in
each treatment (Hsu et al., 2011; Yu et al., 2011), such as the
eukaryotic translation initiation factor 4E-binding protein 1
(eIF4E-BP1) at threonine 37 and 46 and the tumor suppressor
protein programmed cell death 4 (PDCD4) at serine 457. Both
eIF4E-BP1 and PDCD4 are translational repressors known to
act downstream of the mTORC1-ribosomal protein S6 kinase 1
(S6K1) pathway (Brunn et al., 1997; Burnett et al., 1998). Similar
changes in the phosphorylation of eIF4E-BP1 and PDCD4 were
detected by immunoblotting using phosphorylation-specific
antibodies, confirming our findings (Figure S3A). Thus, the
DYRK kinase inhibitor GSK-626616 affects, among others, the
phosphorylation of mRNA-associated proteins and proteins
downstream of mTORC1 signaling.cytoplasmic granules in unstressed cells.
ere exposed to 0.5 mM arsenite for 45 min and immunostained for DYRK3
La cells expressing GFP-DYRK3 were stressed for 45min and immune-stained
nd is retained on SGs by GSK-626616. HeLa cells were stressed for 45 min and
r DYRK3 and PABP1. Scale bars, 10 mm.
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(A) Kinase-inactive DYRK3 is responsible for the occurrence of stress granules during GSK-626616 treatment. HeLa cells were transfected with siRNA against
DYRK3 for 58 hr, stressed for 45 min with 0.5 mM arsenite, and allowed to recover for 240 min in the presence or absence of 1 mMGSK-626616. Immunostaining
for PABP1 allowed the identification and classification of SG-positive cells by automated image analysis and machine-learning. The fraction of SG-positive cells
relative to cells transfected with control, nontargeting siRNA and treated with GSK-626616 are shown as mean ± SD (n = 3).
(B) Kinase-deficient GFP-tagged DYRK3-K218M accumulates on cytoplasmic aggregates and condenses components of mRNA granules.
(C) Schematic representation of full-length DYRK3 and different truncation mutants. Highlighted are the NAPA domains (black), the kinase domain (gray), and the
ATP-binding site K218.
(D and E) The N-terminal domain of DYRK3 induces the appearance of large granules in the absence of stress. HeLa cells expressing GFP-DYRK3-NT were
immunostained for PABP1 or DDX6.
(F) DYRK3 lacking the N terminus does not partition in SGs of HeLa cells stressed for 45 min. Scale bars, 10 mm.DYRK3 Is Required for mTORC1 Activity
To validate the impact of inhibitors targeting DYRK family
kinases on mTORC1 signaling, we evaluated the phosphoryla-
tion state of Thr389 of S6K1, which is considered a direct and
appropriate readout for mTORC1 activity (Burnett et al., 1998).
GSK-626616 treatment abolished the phosphorylation of S6K1796 Cell 152, 791–805, February 14, 2013 ª2013 Elsevier Inc.at Thr389 in nonstimulated HeLa cells, indicating a reduction in
basal mTORC1 activity (Figure 4C). A variety of stimuli, such as
epidermal growth factor (EGF) and insulin addition, can increase
mTORC1 activity above basal levels (Zoncu et al., 2011). GSK-
626616 treatment reduced the phosphorylation of S6K1 at
Thr389 in EGF- and insulin-stimulated HeLa cells, showing that
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mTORC1 activity is impaired (Figure 4D). The extent to which low
concentrations of GSK-626616 inhibited S6K1 phosphorylation
in cells was similar to the effect of a rapamycin derivative
(RAD-001), a well-known inhibitor of mTORC1 (Boulay et al.,
2004). Also harmine treatment was able to interfere with EGF-
stimulated S6K1 phosphorylation, although to a lesser degree
(Figure S3B). Moreover, GSK-626616 treatment interfered with
basal mTORC1 activity, as well as EGF- or insulin-stimulated
mTORC1 activity, in three additional unrelated mammalian cell
lines, indicating a general mechanism that is not cell line-specific
(Figure S3C). As a consequence, treatment of cells with GSK-
626616 leads to a reduction in protein synthesis (Figure S3G).
The mTORC1 pathway integrates many different signaling
inputs, and the DYRK kinase inhibitors may affect several of
those. However, we observed no effect of GSK-626616 treat-
ment on the phosphorylation status of tuberin (TSC2) upon stim-
ulation of cells with either EGF or insulin (Figure 4E). In addition,
we observed no effect on the phosphorylation of AKT or ERK1/2
(Figure S3D). We also found that the PI-3 kinase inhibitor Wort-
mannin had an additive inhibitory effect on mTORC1 activity in
cells treated with GSK-626616 (Figure S3E), further indicating
that the DYRK inhibitor affects mTORC1 via a parallel pathway.
To assess whether the DYRK inhibitors could affect mTORC1
activity via an off-target effect, and not via inhibiting DYRKs,
we considered the few in vitro off targets that these inhibitors
have (Figure S3F). Two possible kinases, namely ERK8 and
RSK3/4, that are weakly inhibited by GSK-626616 in vitro, might
act upstream of mTORC1. However, ERK8 is not inhibited by
harmine (Bain et al., 2007), and both ERK andRSK family kinases
signal tomTORC1 via TSC2, whose phosphorylation status does
not change during GSK-626616 treatment (Figure 4E). Finally,
siRNA- and shRNA-mediated depletion of DYRK3 (but not other
DYRK family kinases, data not shown) also resulted in a reduced
S6K1 phosphorylation (Figures 4F and 4G). This further supports
a specific effect of the inhibitors and indicates that the inhibitory
effect on mTORC1 acts mainly through DYRK3 in a manner that
is independent of the PI3K/AKT and ERK pathways and does not
involve TSC2.
Kinase-Inactive DYRK3 Inhibits mTORC1 by Preventing
Dissociation from SGs
One possibility by which inhibition of DYRK3 may result in an
inhibition of mTORC1 signaling activity is by causing the seques-
tration of mTORC1 in SGs. In S. cerevisiae, dissociation from the
vacuolar membrane and partitioning in SGs affects TORC1
signaling (Takahara and Maeda, 2012). Interestingly, we found
that in human cells, both mTOR and the mTORC1-specific(C) GSK-626616 treatment reduces basal phosphorylation of S6K1 at Thr389. Ser
and the phosphorylation status of S6K1 pThr389 was analyzed by immunoblottin
(D) GSK-626616 treatment reduces EGF- and insulin-induced phosphorylation of S
insulin in the absence or presence of GSK-626616 or RAD-001. See Figure S3.
(E) GSK-626616 treatment does not alter basal, EGF- or insulin-induced phosphor
insulin in the absence or presence of GSK-626616. See Figure S3.
(F) RNAi-mediated depletion of DYRK3 reduces EGF-induced phosphorylation of S
nontargeting siRNA, serumdeprived for the last 14 hr, and treated for 45minwithEG
efficiency was monitored by qRT-PCR and by immunoblotting of lysates of cells, t
(G) Depletion of DYRK3 using different shRNAs reduces insulin-induced phosp
treated 72 hr after transfection for 45 min with insulin. See Figures S3.
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osmotic or oxidative stress, and were retained on SGs by
GSK-626616 treatment (Figures 5A and S4A). Furthermore,
partitioning into SGs reduced the lysosomal localization of
mTORC1 components (Figure S5).
While examining mTORC1 activity during and after stressful
conditions, we observed a reduction in mTORC1 activity during
stress, as reported previously (Inoki et al., 2003), and a hyperacti-
vation of mTORC1 after recovery (Figure 5B). The reactivation of
mTORC1 was blocked by the presence of GSK-626616 during
recovery. To test whether this is a consequence of prolonged
mTORC1 sequestration on SGs, we made use of the SG-dissolv-
ing property of cycloheximide (CHX), which rapidly increases the
rate of SG dissolution and accelerates mTORC1 reactivation (Bu-
chan and Parker, 2009; Takahara and Maeda, 2012). When we
added CHX to cells during recovery from stress, both SG dissolu-
tion and reactivation of mTORC1 were enhanced (Figures 5B and
5C). However, addition of CHX to cells during recovery from stress
in the presence of GSK-626616 led to the dissolution of SGs, but
not to a full reactivation of mTORC1. We obtained similar results
using emetine, which enhanced SG dissolution and mTORC1 re-
activation, but, similar to CHX, led not to the reactivation of
mTORC1 signaling in the presence of GSK-626616 (Figures S4D
and S4E). This indicates that DYRK inhibitors reduce mTORC1
signaling by blockingSGdissolution aswell as by a secondmech-
anism, independent of mTORC1 partitioning in SGs.
DYRK3 Controls mTORC1 by Direct Phosphorylation
of PRAS40
To find the second mechanism by which DYRK3 regulates
mTORC1 activity independent of SG dissolution, we used a mi-
croarray for kinase substrate identification consisting of more
than 9,000 different human recombinant proteins. We identified
26 candidate proteins to be directly phosphorylated in vitro by
wild-type DYRK3 but not by kinase-deficient DYRK3-K218M
(Figure S6A and Table S4). The second most strongly phosphor-
ylated protein identified was the proline-rich AKT substrate of
40 kDa (PRAS40), also known as AKT1 substrate 1, which has
been shown to interact directly with the mTORC1 complex and
to negatively regulate mTOR kinase activity (Sancak et al.,
2007; Vander Haar et al., 2007). Other proteins on the microarray
that are known to regulate mTORC1 activity were not directly
phosphorylated by DYRK3 (Table S4).
Phosphorylation of PRAS40 by AKT1 at Thr246 has been
shown to release it from the mTORC1 complex, thereby abolish-
ing the inhibitory effect of PRAS40 on mTOR, which allows
further activation (Sancak et al., 2007; Vander Haar et al.,um-deprived HeLa cells were treated for 45 min with GSK-626616 or RAD-001
g of cell lysates.
6K1 at Thr389. Serum-deprived HeLa cells were treated for 45minwith EGF or
ylation of TSC2. Serum-deprived HeLa cells were treated for 45minwith EGF or
6K1 at Thr389. HeLa cells were treated for 72 hr with siRNA against DYRK3 or
F.Control cells were simultaneously treatedwithEGF andRAD-001. Knockdown
ransfected with myc-DYRK3. Data are represented as mean ± SD (n = 3).
horylation of S6K1 at Thr389. Transfected, serum-deprived HeLa cells were
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(A) Components ofmTORC1 localize to SGs induced by osmotic stress. Immunofluorescence of mTOR andmyc-RAPTOR shows colocalization with PABP1- and
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during 45 min treatment with 0.6 M sorbitol, and after 240 min recovery in the presence of 1 mM GSK-626616, 50 mg/ml CHX, or both is shown.
(legend continued on next page)
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2007). Using recombinant DYRK3 and PRAS40, we found that
DYRK3 directly phosphorylates Thr246 of PRAS40 in an in vitro
kinase assay (Figure 6A). Addition of GSK-626616 to this assay
blocked the phosphorylation reaction in a dose-dependent
manner (Figure S6B). Moreover, GSK-626616 treatment of
cultured cells, as well as depletion of DYRK3, reduced the phos-
phorylation of PRAS40 at Thr246 in response to EGF treatment
(Figures 6B and 6C).
Using coimmunoprecipitation experiments, we observed that
GSK-626616 increases the fraction of bound PRAS40 to
mTORC1 (Figure 6D), which is known to interfere with binding
and activation of mTOR substrates (Vander Haar et al., 2007).
Furthermore, expression of the T246A mutant of PRAS40, a
phosphodeletion mutant able to block the stimulation of
mTORC1 activity (Sancak et al., 2007), reduced S6K1 phosphor-
ylation before stress and completely prevented mTORC1 reacti-
vation after stress (Figure 6E).
Thus, DYRK3 directly phosphorylates PRAS40 at Thr246,
a phosphorylation site responsible for regulation of PRAS40, re-
sulting in decreased binding of PRAS40 to mTORC1, allowing
activation of mTORC1 signaling in unstressed cells and reactiva-
tion of mTORC1 during stress recovery.
DYRK3 Regulates Its Own Partitioning between SGs and
the Cytosol in a Cyclic Manner through Its Kinase
Activity
Finally, we studied the dynamics of how DYRK3 couples SG par-
titioning with mTORC1 regulation. To reveal this, we performed
fluorescence recovery after photobleaching (FRAP) experi-
ments. In unstressed cells expressing GFP-DYRK3 and display-
ing cytoplasmic speckles, we observed that photobleached
speckles quickly recovered their fluorescence signal to initial
levels within 150 s (Figure 7A). Interestingly, treatment with
GSK-626616 during stress recovery resulted in an entrapment
of 55% of GFP-DYRK3 on granules, which did not exchange
with unbleached cytosolic GFP-DYRK3. Similarly, when we pho-
tobleached the cytoplasmic aggregates induced by the kinase-
deficient mutant of DYRK3 (GFP-DYRK3-K218M), we observed
that 69% of the signal could not be exchanged with unbleached
cytosolic signal. Thus, DYRK3 displays dynamic cycles of parti-
tioning between SGs and the cytosol. Partitioning into SGs
requires the N-terminal domain (deletion of this domain abol-
ishes partitioning in SGs; Figure 3F), while partitioning into the
cytosol requires kinase activity.
Based on these results, we propose the following mechanism
by which DYRK3 couples SG condensation and dissolution with
mTORC1 signaling. When SGs condense, for instance during
stress, DYRK3 will partition in SGs via its N-terminal domain.
Here, it contributes to preventing SG dissolution, leading to par-
titioning of the mTORC1 complex in SGs and thus blocking it
from signaling to downstream effectors. To dissolve SGs, the
kinase activity of DYRK3 is required, leading to partitioning of
the mTORC1 complex in the cytosol, where DYRK3 phosphory-(C) Addition of CHX induces the dissolution of SGs and overcomes the block in
mTOR and PABP1 is shown in cells after 240 min recovery from 45 min 1 M sorbit
during 240 min recovery.
Scale bars, 10 mm.
800 Cell 152, 791–805, February 14, 2013 ª2013 Elsevier Inc.lates PRAS40, which allows reactivation of mTORC1. Thus,
DYRK3 represents a type of regulator that dynamically couples
phase transition-mediated compartmentalization to signal trans-
duction via its kinase activity.
DISCUSSION
In this study, we identify chemical compounds targeting DYRK
family kinases as inhibitors of SG dissolution and show that
these compounds act mainly via DYRK3. We reveal that
DYRK3 has the potential to condense P-granule-like structures
in the cytosol and localizes to SGs after stress. The absence of
DYRK3 does not prevent SG dissolution via its N-terminal
domain, but kinase-inhibited DYRK3 does. This domain is,
when expressed alone or as part of a kinase-deficient mutant
of DYRK3, able to induce the appearance of SG-like structures
even in the absence of stress. We also show that inhibition of
DYRKs affects the phosphorylation status of a number of
mRNA-binding proteins and proteins downstream of mTORC1
signaling. We demonstrate that DYRK3 blocks mTORC1
signaling by keeping mTORC1 partitioned in SGs when inactive,
and phosphorylates the mTORC1 inhibitor PRAS40 when active,
which reduces the binding of PRAS40 to mTORC1 and allows
subsequent mTORC1 activation. Furthermore, we show that
mTORC1 recruitment to SGs during stress reduces its localiza-
tion to lysosomes, which is required for mTORC1 activation by
amino acids (Sancak et al., 2010), and explains how stress,
and inhibition of DYRK3 during stress recovery, generally
reduces mTORC1 activity.
The condensation of SGs via liquid-liquid unmixing depends
on low complexity domains in proteins (Hyman and Simons,
2012; Kato et al., 2012; Weber and Brangwynne, 2012). The
N-terminal domain of DYRK3 contains a predicted low com-
plexity sequence, which may allow partitioning into stress gran-
ules and contribute to liquid-liquid unmixing. This is, however,
not a constitutive property of the DYRK3 protein but is rather
regulated by its own kinase activity in a cyclic manner.
Such a kinase-activity-dependent cycle provides an RNA-
granule-sensing mechanism. When SGs condense during
stress, DYRK3 senses this through its ability to cycle between
SGs and the cytosol. Concomitantly, mTORC1 partitions in
SGs, which prevents signaling to downstream effectors. When
stress signals disappear, the kinase activity of DYRK3 will
dissolve SGs by ‘‘inactivating’’ the SG condensation property of
its N-terminal domain (and possibly by phosphorylating mRNA-
binding proteins) and allowing activation of mTORC1 in the
cytosol by preventing binding to PRAS40. In addition, DYRK3
might be a sensor of RNA granules that are formed under condi-
tions different than stress, such as during cell division, cell polar-
ization, and cell differentiation, linking their appearance to the
control of mTORC1 signaling or other signal transduction path-
ways. We expect that further characterization of the numerous
other proteins whose phosphorylation status is affected bySG dissolution by GSK-626616 after osmotic stress. Immunofluorescence of
ol treatment. Cells were treated with 1 mMGSK-626616, 50 mg/ml CHX, or both
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inhibition of DYRKs, or which can be phosphorylated by DYRK3
in vitro, will provide further details.
Several lines of evidence suggest that the properties of DYRK3
that we have uncovered here are a conserved mechanistic prin-
ciple for DYRK family members. DYRKs have been functionally
linked to the cellular stress response in organisms across the eu-
karyotic kingdom, ranging from nutrient starvation, osmotic
stress, irradiation, and genotoxic stress (Aranda et al., 2011;
Moriya et al., 2001; Seifert and Clarke, 2009; Taira et al., 2007;
Taminato et al., 2002; Zhang et al., 2005). Furthermore, DYRKs
are constitutively active kinases, believed to be regulated by
changing their subcellular localization (Aranda et al., 2011). The
dynamic cycling mechanism of DYRK3 between SGs and the
cytosol shares striking resemblance with that of Pom1,
a DYRK kinase in S. pombe (Hachet et al., 2011). Pom1 cycles
between a membrane-associated state, driven by autophos-
phorylation, and a cytosolic state, driven by phosphatase-
mediated dephosphorylation of its N terminus. Our results
support a similar mechanism for DYRK3. An unphosphorylated
N-terminal low complexity domain might partition in SGs,
whereas autophosphorylation of this domain might abolish this
property, keeping it in the cytosol. This would explain how
kinase-inactive DYRK3 becomes trapped in SGs, as its
N-terminal domain now constitutively partitions into SGs.
However, an autophosphorylation event in the N-terminal
domain of DYRK3 remains to be identified, as well as a phospha-
tase that would dephosphorylate it.
At least two other DYRK family members have been function-
ally linked to mRNA granules. MBK-2, a C. elegans DYRK, has
been observed in speckles in the cytoplasm (Stitzel et al.,
2006) and is essential for the asymmetric distribution of P gran-
ules in the first cell division of the C. elegans embryo (Pang et al.,
2004). This process depends on specifically lowering the
condensation point for P granules at one site of the dividing
embryo (Brangwynne et al., 2009). Analogous to the properties
of DYRK3,MBK-2might thus be involved in P granule condensa-
tion in C. elegans. Furthermore, mammalian DYRK1A accumu-
lates in nuclear splicing speckles (see also Figure S2A) and is
capable of dissolving speckles, depending on its kinase activity
(Alvarez et al., 2003). We also observed that DYRK2, most
closely related to DYRK3, localized to SGs in its inhibited state
where it is partly responsible for blocking SG dissolution (data
not shown).
This suggests that DYRKs are a family of kinases that couple
compartmentalization through liquid phase transitions with
cellular signaling through a novel kinase-dependent cyclic parti-
tioning mechanism. Future work combining structural studies
and detailed mechanistic analysis of DYRK cycling in and out
of liquid-unmixed compartments with the identification of(B) GSK-626616 treatment reduces EGF-induced phosphorylation of PRAS40 a
absence or presence of GSK-626616 or RAD-001.
(C) RNAi of DYRK3 reduces EGF-induced phosphorylation of PRAS40 at Thr246
siRNA, serum deprived for the last 14 hr, and treated for 45 min with EGF.
(D) Binding of PRAS40 to mTORC1 is enhanced by GSK-626616 treatment. mTO
cells in the presence or absence of GSK-626616.
(E) Expression of the mutant PRAS40-T246A reduces mTORC1 signaling. HeL
phosphorylation of S6K1 at Thr389 prior, during 45 min treatment with 0.6 M sor
802 Cell 152, 791–805, February 14, 2013 ª2013 Elsevier Inc.upstream factors that influence this cycle will provide further
insight into how this is utilized in the regulation of various cellular
processes.
EXPERIMENTAL PROCEDURES
Cell Lines and Tissue Culture
HeLa cells were from Marino Zerial (MPI-CBG, Dresden), U2OS cells (RDG3)
from Paul Anderson (Brigham and Women’s Hospital, Boston), and A431 cells
and MEFs were from ATCC (Molsheim Cedex). All cells were maintained at
37C under 5% CO2 in DMEM supplemented with 10% fetal bovine serum
(FBS) and Glutamax. Prior to treatments, cells were washed and serum
deprived for 14 hr.
Stress Granule Condensation and Dissolution Assay
Cells were grown in 384-well plates (for initial screen, Greiner) or 8-well Lab-
Tek chambers (for life cell imaging, VWR) in DMEM containing 10% FBS.
Serum-deprived cells were treated for 45 min with 0.5 mM arsenite, washed
twice with DMEM, and allowed to recover for 240 min in DMEM supplemented
with compound inhibitors at indicated concentrations. Treatment was stopped
by addition of PFA to a final concentration of 4%. SGs were stained by immu-
nofluorescence against PABP1 and images were acquired using on an Im-
ageXpress Micro microscope (Molecular Devices). Life cell imaging was
carried out on a VisiScope Confocal Cell Explorer equipped with a 203
0.75NA Air CFI Plan Apo VC objective (Nikon). Automatic cell detection was
performed using CellProfiler (Carpenter et al., 2006). Features describing
intensities and textures were used for the classification of SG-positive cells
by support vector machine learning using CellClassifier (Ra¨mo¨ et al., 2009).
Immunofluorescence and Confocal Microscopy
HeLa cells were grown on glass coverslips and transfected with indicated
plasmids using Lipofectamine 2000 according to the manufacturer’s instruc-
tion. Cells were fixed by adding PFA to a final concentration of 4% and
permeabilized with 0.1% Triton X-100. Unspecific binding was reduced by
incubation in 1%BSA. Cells were incubated with primary antibodies overnight,
followed by incubation with labeled secondary antibody for 1 hr. Nuclei were
stained using DAPI. Imaging was carried out ona Leica SP5Mid UV-VIS equip-
ped with a 633 1.4-0.6NA DIC, Oil, HCX Plan-Apochromat; Zeiss LSM710
equipped with a 633 1.4NA Oil DIC Plan-Apochromat objective. Images
were processed using ImageJ (http://rsb.info.nih.gov/ij/).
Phosphoproteomics
Cells were exposed to GSK-626616 or DMSO only in DMEM without FBS for
30 min and 12 hr, respectively, washed with PBS and harvested in lysis buffer
(150mMNaCl, 10 mMTris [pH 7.2], 10 mMEDTA, 1mMNa3VO4, 200 nMOca-
daic acid, 20 nM Calyculin A, EDTA free protease inhibitor [Roche], 1 mM
PMSF and 0.1% RapiGest [Waters]). Three replicas were independently
collected and processed separately. The isolation of phosphorylated peptides
using titanium-dioxide, mass spectrometry analysis, and quantitative analysis
was performed as described previously (Huber et al., 2009). Candidate protein
classes were determined using PANTHER database (www.pantherdb.org).
In Vitro Kinase Substrate Identification
ProtoArray Human Protein Microarrays (PAH052406, Invitrogen) were blocked
with 1%BSA in PBS for 3 hr at 4C. Kinase Buffer (100mMMOPS [pH 7.2], 1%
Nonidet P40, 100 mM NaCl, 10 mg/ml BSA, 5 mM MgCl2, 5 mM MnCl2),t Thr246. Serum-deprived HeLa cells were treated for 45 min with EGF in the
. HeLa cells were treated for 72 hr with siRNA against DYRK3 or nontargeting
R immunoprecipitates were prepared from serum-deprived or EGF-stimulated
a cells transfected with myc-PRAS40-T246A were serum deprived and the
bitol, and after 240 min recovery is shown.
PRAS40
AAA
AAA
GSK-626616,
Harmine
Stress granule
AAAAAA
A
AA
AA
A
A
AA
AAAAAA
AA
A
Stress
Protein 
synthesis
Polysome
A
GFP-DYRK3 (n=9)
GFP-DYRK3-K218M (n=7)
GFP-DYRK3 recovery GSK-626616 (n=10)
re
l. 
flu
or
es
ce
nc
e 
[a
.u
.]
1.5
0 50 100 150
0.0
0.5
1.0
GFP-DYRK3 
GFP-DYRK3  
recovery GSK-626616
GFP-DYRK3-K218M - 10.3 s 0 s 20.8 s
39.0 s 101.4 s 153.4 s
- 10.3 s 0 s 20.8 s
39.0 s 101.4 s 153.4 s
- 10.3 s 0 s 20.8 s
39.0 s 101.4 s 153.4 s
B
kinase activity
liquid unmixing
liquid mixing
N-term. domain
time [seconds]
DYRK3
NT
PRAS40
P
DYRK3
mTORC1 mTORC1
Figure 7. Activity-Dependent Dynamic Cycling of DYRK3 on SGs and Mechanism of mTORC1 Reactivation by DYRK3
(A) DYRK3 dynamically associates with mRNA granules. HeLa cells were transfected with GFP-DYRK3 or GFP-DYRK3-K218M 24 hr prior to FRAP experiments.
For stress conditions (FRAP of GFP-DYRK3 on SGs after stress recovery in the presence of GSK-626616), cells were treated for 45 min with 1 M sorbitol and
allowed to recover for 240 min in the presence of 1 mM GSK-626616. Data are represented as mean ± SD. A representative cell for each condition is shown as
a false-color image. Scale bars, 10 mm.
(B) During stressful conditions, stress-induced translational silencing induces the condensation of SGs. DYRK3 will partition in SGs via its N-terminal domain, as
well as mTORC1 components, which prevents mTORC1 signaling. When stress signals are gone, the kinase activity of DYRK3 is required for the dissolution of
SGs and mTORC1 relocation to the cytosol, and for phosphorylating PRAS40, which attenuates the binding of PRAS40 to the TORC1 complex. Combined, this
allows full reactivation of mTORC1 signaling.
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supplemented with 33 nM g33P-ATP and 0.5 mg recombinant GST-DYRK3 or
GST-DYRK3-K218M were added per array and incubated for 1 hr. Arrays
were washed with 0.5% SDS, dried and exposed to Amersham Hyperfilm
(GE Healthcare) for 3 hr. Analysis was carried out with ProtoArray Prospector
(Invitrogen).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, four tables, and two movies and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2013.01.033.
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